Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Oct 06 2025

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received approval from Health Canada for Liothyronine tablets in two dosages. The manufacturing will take place at Zydus’ facility in Ahmedabad SEZ, and the product had significant annual sales in Canada.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases